Skip to main content

Table 2 Summary of case reports of other BTK inhibitors-induced liver injuries

From: Zanubrutinib-induced liver injury: a case report and literature review

Author title and date Nandikolla, 2017 [14] Kahn 2017 [15] Kleijwegt 2019 [16] Tafesh 2019 [17]
Underlying illness Relapsing, refractory CLL Refractory WM Refractory WM Refractory WM
BTK inhibitor Ibrutinib Ibrutinib Ibrutinib Ibrutinib
Patient’s age and gender 62-year-old male 59-year-old female 48-year-old female 77-year-old Female
Time of liver injury since starting BTK inhibitor 2 weeks 9 months 11 weeks 2 months
Pattern of DILI Hepatocellular Hepatocellular Hepatocellular Hepatocellular
Causality assessment/RUCAM 1 “Unlikely”a 7 “probable” 8 “probable”a 6 “possible”a
Liver histology Centrilobular intrahepatic and canalicular cholestasis, ceroid-laden macrophages and minor apoptosis Acute hepatitis with mixed acute and chronic inflammation and hepatocellular cholestasis Not performed Mixed inflammatory cell infiltrate, lobular disarray, hepatocellular ballooning, focal canalicular cholestasis, and necrosis
Intervention Ibrutinib stopped Ibrutinib stopped Ibrutinib stopped Ibrutinib stopped + oral prednisolone 60 mg daily for 12 days, then tapered down.
Outcome Liver enzymes improved but did not normalise, and the patient died from the original illness. Liver enzymes normalised after 60 days Liver enzymes normalised after 5 weeks of stopping Ibrutinib Liver enzymes normalised after 7 weeks and remained normal after 3 months
  1. aRUCAM score was not reported; it was calculated based on the published data in the case report